291 related articles for article (PubMed ID: 21245657)
1. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
[TBL] [Abstract][Full Text] [Related]
2. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
McNeil LK; Donald RGK; Gribenko A; French R; Lambert N; Harris SL; Jones TR; Li S; Zlotnick G; Vogel U; Claus H; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Wang X; Vuong J; Mayer LW; Pride MW; Jansen KU; Anderson AS
mBio; 2018 Mar; 9(2):. PubMed ID: 29535195
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
[TBL] [Abstract][Full Text] [Related]
4. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
Pajon R; Lujan E; Granoff DM
Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
[TBL] [Abstract][Full Text] [Related]
5. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
Rossi R; Beernink PT; Giuntini S; Granoff DM
Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
[TBL] [Abstract][Full Text] [Related]
7. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
[TBL] [Abstract][Full Text] [Related]
8. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
Bettinger JA; Liberator P; Halperin SA; Vaudry W; Sadarangani M; Hao L; Lambert N; Jansen KU; Anderson AS; Tsang R;
Vaccine; 2020 Feb; 38(8):2026-2033. PubMed ID: 31983586
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
10. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.
Hoiseth SK; Murphy E; Andrew L; Vogel U; Frosch M; Hellenbrand W; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Mayer LW; Wang X; Macneil JR; York L; Tan CY; Jansen KU; Anderson AS
Pediatr Infect Dis J; 2013 Oct; 32(10):1096-101. PubMed ID: 23694830
[TBL] [Abstract][Full Text] [Related]
11. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
[TBL] [Abstract][Full Text] [Related]
13. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.
Konar M; Granoff DM; Beernink PT
J Infect Dis; 2013 Aug; 208(4):627-36. PubMed ID: 23715659
[TBL] [Abstract][Full Text] [Related]
14. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
[TBL] [Abstract][Full Text] [Related]
15. Use of expanded
Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
[TBL] [Abstract][Full Text] [Related]
16. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.
Anderson AS; Hao L; Jiang Q; Harris SL; Jones TR; Perez JL; York L; Eiden J; Jansen KU
Hum Vaccin Immunother; 2013 Mar; 9(3):471-9. PubMed ID: 23249817
[TBL] [Abstract][Full Text] [Related]
17. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
[TBL] [Abstract][Full Text] [Related]
18. Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.
Bianchi F; Veggi D; Santini L; Buricchi F; Bartolini E; Lo Surdo P; Martinelli M; Finco O; Masignani V; Bottomley MJ; Maione D; Cozzi R
FASEB J; 2019 Nov; 33(11):12099-12111. PubMed ID: 31442074
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A; Balmer P; York LJ
Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
[TBL] [Abstract][Full Text] [Related]
20. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
Giuntini S; Pajon R; Ram S; Granoff DM
Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
